Comparative Pharmacology
Head-to-head clinical analysis: JANUMET versus NESINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JANUMET versus NESINA.
JANUMET vs NESINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Janumet is a combination of sitagliptin, a DPP-4 inhibitor, and metformin, a biguanide. Sitagliptin increases incretin levels (GLP-1, GIP), enhancing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Inhibitor of dipeptidyl peptidase-4 (DPP-4), preventing inactivation of incretin hormones (GLP-1, GIP), thereby increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner.
Initial dose: 50 mg sitagliptin/500 mg metformin hydrochloride twice daily orally with meals. Dose may be increased up to 50 mg sitagliptin/1000 mg metformin twice daily based on glycemic response and tolerability.
25 mg orally once daily.
None Documented
None Documented
Sitagliptin: 12.4 hours (terminal). Clinical context: supports once-daily dosing, but half-life increases in renal impairment. Metformin: 6.2 hours (terminal). Shorter half-life requires multiple daily dosing; prolonged in renal impairment.
Terminal elimination half-life: 12.4–26.1 hours (mean ~21 hours); supports once-daily dosing
Sitagliptin: 87% renal (unchanged), 13% fecal (metabolites). Metformin: 90-100% renal (unchanged), <5% fecal.
Renal: 87% (75% as unchanged drug, 12% as inactive metabolites); Fecal: <1%
Category C
Category C
DPP-4 Inhibitor/Biguanide Combination
DPP-4 Inhibitor